ASX Information
For ASX shareholders, our shareholder registry is Link Market Services.
Log on to our share registry’s website at https://investorcentre.linkmarketservices.com.au or email Market Services at LMSComms@linkmarketservices.com.au to find about your shareholding.
Important information for shareholders as to how you elect to receive your communications from Telix
SGX Information
On 31 July 2024, convertible notes (or convertible bonds) issued by Telix pursuant to an offering circular (https://links.sgx.com/1.0.0/prospectus-circulars/53036) were listed on the Official List of the Singapore Exchange Securities Trading Limited (SGX). All information which may have a material effect on the price or value of the convertible bonds or on an investor’s decision whether to trade in the bonds, together with other information announced to the SGX as relevant to Telix’s continuing SGX listing obligations can be accessed here.
ADR Information
Telix Pharmaceuticals has a Level II American Depositary Receipt (ADR) program facility trading on the Nasdaq Stock Market (Nasdaq) in the United States.
Telix’s ADRs trade under the symbol TLX. Each Telix ADR is equivalent to 1 ordinary share of Telix traded on the Australian Securities Exchange.
An ADR is a negotiable United States certificate representing ownership of shares in a non-U.S. corporation. ADRs are quoted and traded in U.S. dollars in the United States securities market. Registered with the United States Securities and Exchange Commission (SEC), investors in the U.S. and elsewhere can purchase Telix ADRs on Nasdaq.
JPMorgan Chase Bank, N.A. (JPMorgan) is the depositary bank that manages the ADR program on behalf of Telix.
FAQs
For more information on Telix’s ADRs, please see the FAQs below: